FRACTYL HEALTH, INC. 8-K

What Happened
Fractyl Health, Inc. (GUTS) filed an 8-K on March 17, 2026 disclosing that on March 13, 2026 Nasdaq’s Listing Qualifications Department notified the company its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the minimum bid price was below $1.00 for the prior 30 consecutive business days. Nasdaq has given the company a 180‑calendar‑day compliance period—until September 9, 2026—to cure the deficiency by achieving a closing bid of $1.00 or more for at least 10 consecutive business days. The notice does not currently affect the listing of the company’s shares.

Key Details

• Notice date: March 13, 2026; 8‑K filed: March 17, 2026 (signed by CEO Harith Rajagopalan).
• Deficiency: minimum bid price below $1.00 for 30 consecutive business days (Nasdaq Rule 5450(a)(1)).
• Cure requirement: close at $1.00+ for 10 consecutive business days within 180 days (deadline Sept 9, 2026).
• If not cured, options include applying to transfer to the Nasdaq Capital Market (Transfer Application fee $5,000) and/or effecting a reverse stock split; Nasdaq may delist if it determines the deficiency won’t be cured, subject to an appeal process.

Why It Matters
A sustained failure to meet Nasdaq’s $1.00 minimum bid rule can lead to delisting, which could reduce liquidity and make the stock harder to trade. The company currently remains listed and plans to monitor its share price and consider remedies (e.g., transfer to the Nasdaq Capital Market or a reverse split). Investors should be aware of the deadline (Sept 9, 2026) and that corporate actions to regain compliance could affect share count and market behavior.